HARMONi-6 Ivonescimab + Chemo vs. Tislelizumab + Chemo in 1L Squamous

HARMONi-6: Ivonescimab + Chemo vs. Tislelizumab + Chemo in 1L Squamous NSCLC, Featured at ESMO 2025 Presidential Symposium

Summit Therapeutics Inc. announced that data from the Phase III HARMONi-6 trial will be highlighted during the prestigious Presidential Symposium at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, taking place in Berlin, Germany, from October 17–21, 2025.…

Read MoreHARMONi-6: Ivonescimab + Chemo vs. Tislelizumab + Chemo in 1L Squamous NSCLC, Featured at ESMO 2025 Presidential Symposium
Kinea Bio Advances Dysferlinopathy Gene Therapy with $1.1M

Kinea Bio Advances Dysferlinopathy Gene Therapy with $1.1M Investment, Solid Biosciences Deal

Kinea Bio Inc., a biotechnology company dedicated to developing transformative genetic medicines, announced today two major milestones that significantly advance its lead gene therapy program for dysferlinopathy, a rare and debilitating neuromuscular disease. The company has secured a commitment of…

Read MoreKinea Bio Advances Dysferlinopathy Gene Therapy with $1.1M Investment, Solid Biosciences Deal
Drug Farm, Cincinnati Children’s Partner on ALPK1

Drug Farm, Cincinnati Children’s Partner on ALPK1 Inhibitor for Heart Disease and Blood Cancers

Drug Farm, a private biotechnology company pioneering the use of genetics and artificial intelligence to discover and develop innovative immune-modulating therapies, announced today that it has entered into a Material Transfer Agreement (MTA) with Cincinnati Children’s Hospital Medical Center (CCHMC).…

Read MoreDrug Farm, Cincinnati Children’s Partner on ALPK1 Inhibitor for Heart Disease and Blood Cancers
Aptar Pharma’s Unidose Device Powers FDA Approval

Aptar Pharma’s Unidose Device Powers FDA Approval of Enbumyst™, First Intranasal Diuretic

Aptar Pharma, a global leader in drug delivery and active material science solutions, announced that its Unidose Liquid System (UDS) has been selected as the delivery technology for Enbumyst™ (Bumetanide Nasal Spray) 0.5 mg, recently approved by the U.S. Food…

Read MoreAptar Pharma’s Unidose Device Powers FDA Approval of Enbumyst™, First Intranasal Diuretic